Nanox to Debut Nanox.ARC X and Preview New AI Tools at RSNA 2025

NANO-X IMAGING LTD (Nasdaq: NNOX), a medical imaging technology company focused on broadening access to advanced diagnostics, will present its latest innovations at the upcoming Radiological Society of North America (RSNA) 2025 Annual Meeting in Chicago. Headlining its exhibition is the Nanox.ARC X, a multi-source digital tomosynthesis system cleared by the FDA earlier this year, alongside a preview of new artificial intelligence tools in development.

The Nanox.ARC X system brings 3D imaging capabilities to routine clinical settings by offering an alternative to CT scans that significantly reduces both cost and radiation exposure. With FDA 510(k) clearance granted in April 2025, the system is approved for general radiographic use, including musculoskeletal, pulmonary, intra-abdominal, and paranasal sinus imaging. Visitors to Booth #3914 (South Hall Level 3) will have the chance to see the system in action during live demonstrations scheduled every 30 minutes throughout the event.

In addition to showcasing the Nanox.ARC X, the company will highlight its end-to-end imaging solution, which combines the tomosynthesis platform with a growing suite of AI-driven analysis tools. These tools—designed to interpret routine CT scans—aid in the early detection of chronic conditions and complement the system’s image acquisition capabilities.

Nanox will also preview several new additions to its AI portfolio. Among them is a pulmonary nodule detection solution currently in development for integration with the ARC X platform. The company is also working on standalone AI tools for aortic valve calcification measurement and body composition analysis, signaling a continued expansion into comprehensive, software-driven imaging support.

“We are excited to unveil the Nanox.ARC X system to the radiology community for the first time,” said Erez Meltzer, CEO and Acting Chairman of Nanox. “The system bridges the gap between conventional X-rays and CT scans, bringing advanced 3D imaging to everyday care settings where it hasn’t been practical before. We will also be highlighting our expanding AI portfolio, featuring two new AI innovations in development. We’re delivering on our vision to leverage our AI and proprietary digital X-ray source technology to make advanced medical imaging accessible to more patients, in more places.”

The company’s presence at RSNA 2025 aims to reinforce its long-term commitment to democratizing medical imaging by integrating hardware and software innovation into a single, scalable solution.